<DOC>
	<DOC>NCT00493532</DOC>
	<brief_summary>This single arm study will assess the efficacy and safety of quarterly intravenous Bonviva in women with post-menopausal osteoporosis. All patients will receive Bonviva 3mg i.v. every 3 months. The anticipated time on study treatment is 3-12 months, and the target sample size is 100 individuals.</brief_summary>
	<brief_title>A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<criteria>postmenopausal women with osteoporosis; &lt;=80 years of age; naive to oral bisphosphonates, or have discontinued daily and/or weekly bisphosphonate treatment for &gt;1 year. metabolic bone disease other than postmenopausal osteoporosis; treatment with other drugs affecting bone metabolism within last 6 months; previous or current malignant disease (except for adequately treated cancer in situ of the cervix, or basal or squamous cell skin cancer).</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>